About Zai Lab
Zai Lab is a publicly listed company based in Shanghai (China) founded in 2013. Antibody-based therapies for cancers and inflammatory diseases are developed. Zai Lab has raised $160 million across 3 funding rounds from investors including Kleiner Perkins, Orbimed and Qiming Venture Partners. The company has 1,870 employees. Its website zailaboratory.com draws about 19 thousand monthly visits. Zai Lab offers products and services including Transformative Medicines and Innovative Therapies. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is ZAI LAB LTD.
Company details
Zai Lab was founded in 2013 in Shanghai, China, within the biotechnology sector. Innovative drugs targeting anti-cancer and anti-inflammatory conditions are developed, including antibody-based therapies for hepatocellular carcinoma and lung cancer. Additional products address asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, and graft versus host disease. Operations center on research and development of these therapeutic solutions in the pharmaceutical industry.
- Headquarters Shanghai, China
- Employees 1,870
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website zailaboratory.com
- Social LinkedIn X
- Legal Name Zai Lab Ltd.
- Annual Revenue$461.19 M (USD)15.23as on Dec 31, 2025
- Net Profit-$176 M (USD)31.79as on Dec 31, 2025
- EBITDA-$205.55 M (USD)21.55as on Dec 31, 2025
- Total Equity Funding$160M (USD)
in 3 rounds
- Latest Funding Round$30M (USD), Series C
Jun 2017
- InvestorsKleiner Perkins
& 8 more
- Employee Count1,870
Products & Services of Zai Lab
Zai Lab offers a comprehensive portfolio of products and services, including Transformative Medicines and Innovative Therapies.
Develops treatments for oncology and infectious diseases through research.
Focuses on immunology and neuroscience solutions via clinical pipelines.
Funding Insights of Zai Lab
Zai Lab has successfully raised a total of $160M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $160M
- Total Rounds 3
- Last Round Series C — $30M
- First Round $30M
(Aug 2014)
- Investors Count 9
All 3 funding rounds of Zai Lab with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2017 | $30M | Series C | – | – | |
| Jan 2016 | $100M | Series B | – | – | |
| Aug 2014 | $30M | Series A | – | – |
9 investors in total: 9 institutional.
Investors in Zai Lab
Zai Lab has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Orbimed and Qiming Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
TF Capital is engaged in biotech investment and strategic support. | tfcapital.net | Shanghai, China | ||
| advantechcapital.com | ||||
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Sourcing and deploying capital for real estate investments and developments. | cormorant-capital.com | New York, United States | ||
HongShan is engaged in venture capital investments for innovative companies. | hongshan.com | Hong Kong, China |
Investor details for Zai Lab
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Zai Lab
88 people are tracked at Zai Lab (55 in leadership, 9 in board & advisors, 24 in team); the tracked headcount is 1,870.
| Name | Role | Group |
|---|---|---|
Samantha Du | Founder, Chairwoman & CEO | Leadership |
Ning Wang | Senior Medical Director, Oncology | Leadership |
Yajing Chen | CFO | Leadership |
Josh Smiley | President & COO | Leadership |
Jian Wang | Associate Director | Leadership |
Ning Xu | EVP, Head of Clinical Operations | Leadership |
Rafael G. Amado | President & Head of Global Oncology Research & Development | Leadership |
Andrew Zhu | Chief Commercial Officer, Greater China | Leadership |
Diana Landa | Vice President, Regulatory Affairs | Leadership |
Daphne Gao | Associate Director Of Medical Writing & Medical Science | Leadership |
Fangming Zheng | Sr. Director, Cmc/analytical | Leadership |
Xia P. | Global Head Of Clinical Pharmacology, Pharmacometrics, And Bioanalysis | Leadership |
James Yan | COO, R&D | Leadership |
Lanna C. | Executive Director, Clinical Operations | Leadership |
Nathan Ihle | Executive Director, Cancer Biology | Leadership |
Clarence Eng | Executive Director, Head Of Clinical Operations | Leadership |
Ellen Ye | Sr Director, Clinical Operation | Leadership |
Jenny Tu | Clinical Project Director | Leadership |
Michelle Wagner Gardinier | Director, Cancer Biology | Leadership |
Yi Qing Zhuang | Vp, Head Of ONCO Program And Portfolio Management | Leadership |
68 more people are available in the full profile.
Complete people profiles for Zai Lab
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Zai Lab
Zai Lab is a publicly listed company on the HKEX with ticker symbol 9688 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Sep 2020
- Listed onHKG: 9688
- Listed entityZai Lab Ltd.
- Exchange sectorHealth technology
- ISINKYG9887T1168
- Share price17.45 HKD (-8.11% on the day) · 2026-10-14
- Market capitalisation21,564,887,963.00 HKD
- EPS (diluted, trailing year)-1.33 HKD
- Volume (last session)4,557,300
Financials of Zai Lab
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 3.59B HKD | -1.37B HKD | -1.60B HKD |
| 2024 | 3.11B HKD | -2.01B HKD | -2.04B HKD |
| 2023 | 2.09B HKD | -2.62B HKD | -2.81B HKD |
| 2022 | 1.68B HKD | -3.47B HKD | -3.04B HKD |
| 2021 | 1.12B HKD | -5.48B HKD | -5.34B HKD |
Detailed financial statements for Zai Lab
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Zai Lab
4 dated milestones of Zai Lab across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Zai Lab is founded.
- Funding First funding round of $30.0M.
- Funding Latest funding round, Series C, of $30.0M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Zai Lab
The website of Zai Lab (zailaboratory.com) receives about 18.8K visits a month and ranks #1,021,523 among all websites worldwide, #1,256 in Biotechnology and Pharmaceuticals.
- Monthly visits18.8K
▼ 37.6% vs previous month
- Unique visitors10.9K
per month
- Global rank#1,021,523
among all websites
- Category rank#1,256
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit2.1
- Average visit28 sec
- DevicesDesktop 19% · Mobile 81%
Websites whose visitors overlap most with Zai Lab. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
phirda.com | phirda.com | 100% | #762,386 | – | |
| argenx.com | 100% | 62.9K | #669,034 | View details | |
| hutch-med.com | 100% | 13.2K | #1,517,293 | View details | |
ioncol.com | ioncol.com | 60% | #3,568,184 | – | |
memoinoncology.com | memoinoncology.com | 60% | #2,893,156 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Zai Lab
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zai Lab
Complete news archive for Zai Lab
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zai Lab
Zai Lab was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Zai Lab is headquartered in Shanghai, China.
Zai Lab is a funded company, having raised a total of $160M across 3 funding rounds to date. The company's 1st funding round was a Series A of $30M, raised on Aug 2014.
Zai Lab has 1,870 employees.
Annual revenue of Zai Lab is $461.19M as on Dec 31, 2025.
Zai Lab was founded in 2013 in Shanghai, China, within the biotechnology sector. Innovative drugs targeting anti-cancer and anti-inflammatory conditions are developed, including antibody-based therapies for hepatocellular carcinoma and lung cancer. Additional products address asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, and graft versus host disease. Operations center on research and development of these therapeutic solutions in the pharmaceutical industry.
Zai Lab offers Transformative Medicines and Innovative Therapies.
Yes, Zai Lab is publicly traded on HKEX under the ticker symbol 9688.
Zai Lab has 9 investors. Key investors include Kleiner Perkins, Orbimed, Qiming Venture Partners, Vivo Capital, and Rock Springs Capital.
Zai Lab operates through Zai Lab Ltd.